ClinicalTrials.gg
RecruitingNCT07881965Updated Oct 26, 2026

A Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

A Phase 3 interventional study of WS016 in Hyperkalemia, sponsored by Waterstone Pharmaceutical (Wuhan) Co., LTD.. Recruiting at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Waterstone Pharmaceutical (Wuhan) Co., LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 26, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hyperkalemia with a site in China — 7 open to participants now, 8 under way, 3 of them phase 3. Hyperkalemia · China.

Planned enrollment
6th of 13
300 · median 270
Started
2026
the only one that year
Phase 3
8 of 20
3 open now
Registered
20th of 20
by date
Lead sponsor
4 of 20
Waterstone Pharmaceutical (Wuhan) Co., LTD.

Among the 20 studies in Hyperkalemia with a site in China, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 3, and was the 20th registered.

Hyperkalemia

133 studies on the registry are indexed under Hyperkalemia; 25 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

7 of the 20 studies in Hyperkalemia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 15 Hyperkalemia studies recruiting now, 10 (67%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hyperkalemia with a site in China, or all of them as a file.
02

Study summary

This clinical trial is an open-label, consisting of 2 phases, corrective phase (CP) and a maintenance phase (MP). The corrective phase aims to correct hyperkalemia within 24 to 72 hours, the maintenance phase aims to maintain the serum potassium level of subjects in the normal range for 12-month extension study carried out in participants who come from the first phase and meet certain inclusion criteria.

Read the detailed description

Eligible participants with hyperkalemia will first receive oral WS016 (12g) three times daily, over 24 to 72 hours.

After the corrective treatment, participants whose serum potassium is within the normal range will be enter the open-label maintenance phase to receive WS016 for 12-month, starting at 12g once daily, with subsequent dose adjustments based on serum potassium levels.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (male or female) aged 18 years and older;
  • Participants with a serum potassium concentration >5.0 mmol/L (serum potassium concentration will be measured using the i-STAT portable biochemical analyzer in screening period);
  • Participants who have negative pregnancy test result at screening and ensure the use of during the trial;
  • Participants who understand and voluntarily sign the Form.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a history of severe drug allergy, or are definitely allergic to the product or its ingredients;
  • Participants who have pseudohyperkalemia, such as serum potassium increasing caused by hemolysis of blood samples due to improper blood- Page 3 of 8 collection methods (such as too tight pressure pulse band banding, too heavy local rubbing, repeated fist clenching-loosening hands), hemolysis of blood samples due to difficulty in venipuncture or trauma, and severe leukocytosis (>50 × 10\^9/L) or thrombocytosis (>500 × 10\^9/L);
  • Participants with acute hyperkalemia caused by conditions such as tumor lysis syndrome or hemolysis and so on;
  • Participants suffering from severe cerebrovascular diseases, such as cerebral infarction or cerebral hemorrhagic disease, or those who may have language disorder or delayed responses due to a history of cerebrovascular disease and thus are unable to communicate normally during screening;
  • Participants who have suffered from myocardial infarction, or have undergone interventional cardiac procedures or coronary artery bypass grafting for coronary atherosclerotic heart disease within 3 months prior to screening; or participants who have heart failure and are in cardiac function class IV (, NYHA classification criteria) at screening;
  • Patients with cardiac arrhythmia requiring urgent treatment at screening, such as ventricular tachycardia, ventricular fibrillation, II-III degree atrioventricular block, severe bradycardia (heart rate \<40 bpm), or patients with significant prolongation of PR interval (PR interval prolonged to more than 0.25 seconds in the absence of atrioventricular block), decrease or disappearance of P wave amplitude, and widening of QRS wave (widening to more than 0.14 seconds in the absence of bundle branch block) indicated by the at screening;
  • Patients who have previously undergone major gastrointestinal surgery such as subtotal gastrectomy, short bowel syndrome and other diseases affecting the normal peristalsis of the gastrointestinal tract; or patients with intractable constipation;
  • Patients who have received treatment with polypropylene exchange resin or sodium zirconium cyclosilicate and other similar drugs within 3 days before screening;
  • Patients who participated in other clinical trials of drugs or devices not approved for marketing within 3 months prior to the first dose;
  • Participants who are receiving dialysis;
  • Patients with severe hepatic impairment: serum or aspartate aminotransferase more than 3 times the ;
  • Patients who are unable to complete this part of the trial as assessed by the investigator due to any other disease or psychiatric condition; or patients whose participation in the trial is assessed by the investigator as having a risk that far outweighs the benefit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    WS016

    Drug: WS016

Interventions

  • DrugWS016

    There is no other interventions in this clinical study.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with the mean serum potassium ≤5.0 mmol/L during maintenance phase

    Time frame: Maintenance phase 12-month

Secondary outcomes

  1. Adverse events, serious adverse events, treatment-related adverse events, treatment-related serious adverse events and their incidences in subjects in the corrective phase

    Time frame: Through 24 to 72 hours corrective phase

  2. Adverse events, serious adverse events, treatment-related adverse events, treatment-related serious adverse events and their incidences in subjects in the Maintenance phase

    Time frame: Through 12-month Maintenance phase

  3. Mean change from baseline in serum potassium at all time points of corrective phase

    Time frame: Through 24 to 72 hours corrective phase

  4. Exponential rate of change in serum potassium during the corrective phase

    Time frame: Through 24 to 72 hours corrective phase

07

Study locations

12 of 50 sites recruiting
  • Investigator Site 20
    Anqing, Anhui 246000, China
    Not yet recruiting
  • Investigator Site 18
    Hefei, Anhui 230000, China
    Not yet recruiting
  • Investigator Site 19
    Wuhu, Anhui 241000, China
    Recruiting
  • Investigator Site 42
    Xuancheng, Anhui 242000, China
    Not yet recruiting
  • Investigator Site 50
    Beijing, Beijing Municipality 100000, China
    Recruiting
  • Investigator Site 44
    Xiamen, Fujian 361000, China
    Not yet recruiting
  • Investigator Site 45
    Lanzhou, Gansu 730000, China
    Not yet recruiting
  • Investigator Site 22
    Guangzhou, Guangdong 510000, China
    Recruiting
  • Investigator Site 23
    Shantou, Guangdong 515000, China
    Not yet recruiting
  • Investigator Site 21
    Zhanjiang, Guangdong 524000, China
    Not yet recruiting
  • Investigator Site 35
    Guiyang, Guizhou 550000, China
    Not yet recruiting
  • Investigator Site 02
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
  • Investigator Site 03
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
  • Investigator Site 04
    Luoyang, Henan 471000, China
    Not yet recruiting
  • Investigator Site 06
    Nanyang, Henan 473000, China
    Not yet recruiting
  • Investigator Site 07
    Puyang, Henan 457000, China
    Not yet recruiting
  • Investigator Site 41
    Sanmenxia, Henan 472000, China
    Recruiting
  • Investigator Site 05
    Xinxiang, Henan 453000, China
    Not yet recruiting
  • Investigator Site 26
    Huangshi, Hubei 435000, China
    Recruiting
  • Investigator Site 48
    Jingzhou, Hubei 434100, China
    Not yet recruiting
  • Investigator Site 27
    Shiyan, Hubei 442000, China
    Not yet recruiting
  • Investigator Site 24
    Wuhan, Hubei 430000, China
    Recruiting
  • Investigator Site 25
    Wuhan, Hubei 430000, China
    Not yet recruiting
  • Investigator Site 30
    Zhuzhou, Hunan 412000, China
    Recruiting
  • Investigator Site 37
    Hohhot, Inner Mongolia 010000, China
    Not yet recruiting
  • Investigator Site 10
    Nanjing, Jiangsu 210000, China
    Recruiting
  • Investigator Site 11
    Nanjing, Jiangsu 210000, China
    Recruiting
  • Investigator Site 14
    Nantong, Jiangsu 226000, China
    Not yet recruiting
  • Investigator Site 12
    Suzhou, Jiangsu 215000, China
    Not yet recruiting
  • Investigator Site 13
    Yangzhou, Jiangsu 225000, China
    Not yet recruiting
  • Investigator Site 29
    Ganzhou, Jiangxi 341000, China
    Not yet recruiting
  • Investigator Site 28
    Nanchang, Jiangxi 330000, China
    Not yet recruiting
  • Investigator Site 49
    Pingxiang, Jiangxi 337000, China
    Not yet recruiting
  • Investigator Site 38
    Shenyang, Liaoning 110000, China
    Recruiting
  • Investigator Site 36
    Yinchuan, Ningxia 750000, China
    Not yet recruiting
  • Investigator Site 39
    Tai’an, Shandong 271000, China
    Not yet recruiting
  • Investigator Site 08
    Tancheng, Shandong 276100, China
    Recruiting
  • Investigator Site 40
    Weifang, Shandong 261000, China
    Not yet recruiting
  • Investigator Site 09
    Shanghai, Shanghai Municipality 200000, China
    Not yet recruiting
  • Investigator Site 47
    Shanghai, Shanghai Municipality 20000, China
    Not yet recruiting
  • Investigator Site 46
    Xi'an, Shannxi 710000, China
    Not yet recruiting
  • Investigator Site 43
    Taiyuan, Shanxi 030000, China
    Not yet recruiting
  • Investigator Site 31
    Chengdu, Sichuan 610000, China
    Not yet recruiting
  • Investigator Site 33
    Chengdu, Sichuan 610000, China
    Not yet recruiting
  • Investigator Site 33
    Deyang, Sichuan 618000, China
    Not yet recruiting
  • Investigator Site 34
    Yibin, Sichuan 644000, China
    Not yet recruiting
  • Investigator Site 15
    Jiaxing, Zhejiang 314000, China
    Not yet recruiting
  • Investigator Site 16
    Ningbo, Zhejiang 315000, China
    Not yet recruiting
  • Investigator Site 17
    Ningbo, Zhejiang 315010, China
    Not yet recruiting
  • Investigator Site 01
    Beijing, 100000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2029, 28 months after the start.

Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 20, 2026
StartActual
Sep 25, 2026
Primary completionEst.
Feb 20, 2029
CompletionEst.
Mar 30, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
A Two-Part, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
Oct 26, 2026
Registered
First appeared on the registry
Oct 20, 2026
Show all 2 updates
  1. Oct 26, 2026
    Title A Two-Part, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07881965
Lead sponsor
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Sep 25, 2026
Primary completion
Feb 20, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Waterstone Medical Center
Contact
mpr2024_waterstone@waterstonepharma.com
+86 27 87531661

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: WS016

Start the discussion